How Finerenone Improves Kidney Function
Finerenone slows kidney function decline by reducing inflammation and fibrosis through selective mineralocorticoid receptor antagonism, resulting in a 23% reduction in composite kidney outcomes (kidney failure, sustained ≥57% decrease in eGFR, or renal death) compared to placebo in patients with type 2 diabetes and chronic kidney disease. 1
Mechanism of Kidney Protection
Finerenone works through nonsteroidal mineralocorticoid receptor (MR) antagonism that specifically targets pathological MR overactivation in the kidneys. Unlike older steroidal MRAs (spironolactone, eplerenone), finerenone's selective action blocks the inflammatory and fibrotic pathways that drive progressive kidney damage in diabetic kidney disease 2.
The drug demonstrates its kidney-protective effects through:
- Reduction in albuminuria: Finerenone produces rapid and sustained decreases in urinary albumin-to-creatinine ratio (UACR), with many patients achieving ≥30% reduction from baseline by month 4, which directly mediates the treatment effect on kidney outcomes 3
- Slowing eGFR decline: The mean annual rate of eGFR decline is reduced by 0.7 mL/min/1.73 m² compared to placebo (from -4.0 to -3.3 mL/min/1.73 m²) 4
- Prevention of kidney failure: 36% reduction in end-stage kidney disease (ESKD) in FIDELIO-DKD (0.9% vs 1.3%; HR 0.64) 1
Clinical Evidence Base
The FIDELITY pooled analysis (N=13,171 patients) provides the most robust evidence across the spectrum of CKD severity. This analysis demonstrated a 23% reduction in the composite kidney outcome (HR 0.77; 95% CI 0.67-0.88; P=0.0002) over a median 3.0-year follow-up 1, 5.
Key trial findings:
- FIDELIO-DKD: Focused on advanced CKD (mean eGFR 44.3 mL/min/1.73 m²), showing 18% reduction in primary kidney composite (HR 0.82; 95% CI 0.73-0.93; P=0.001) 6
- FIGARO-DKD: Enrolled earlier-stage CKD (mean eGFR 67.8 mL/min/1.73 m²), demonstrating 36% reduction in ESKD (HR 0.64) 7
The kidney benefits occur independently of baseline glycemic control (HbA1c <7.5% vs ≥7.5%), insulin use, or background SGLT2 inhibitor therapy 8.
Practical Implementation
Initiation criteria per 2025 KDIGO guidelines 9:
- Type 2 diabetes with albuminuria (UACR >30 mg/g)
- eGFR >25 mL/min/1.73 m²
- Serum potassium ≤4.8 mmol/L (or ≤5.0 mmol/L per FDA label)
- Already on maximum tolerated RAS inhibitor dose
Dosing algorithm:
- Start 10 mg daily if eGFR 25-59 mL/min/1.73 m²
- Start 20 mg daily if eGFR ≥60 mL/min/1.73 m²
- Uptitrate from 10 mg to 20 mg after 1 month if potassium ≤4.8 mmol/L and eGFR stable 9
Monitoring schedule:
- Check potassium at 1 month after initiation or dose change
- Then monitor potassium every 4 months
- Continue finerenone if potassium ≤5.5 mmol/L
- Hold if potassium >5.5 mmol/L; restart at 10 mg when potassium ≤5.0 mmol/L 9
Position in Treatment Algorithm
According to 2025 guidelines, SGLT2 inhibitors remain first-line after RAS inhibitors due to larger effect sizes on both kidney and cardiovascular outcomes 10. However, finerenone should be added when:
- Persistent albuminuria despite SGLT2 inhibitor therapy
- SGLT2 inhibitor intolerance or contraindication
- High residual risk (advanced CKD with significant albuminuria)
Finerenone can be safely combined with SGLT2 inhibitors and GLP-1 RAs, as the independent beneficial effects of each medication are preserved regardless of background therapy 1, 11.
Safety Considerations
Hyperkalemia is the primary concern but is manageable:
- Incidence: 10.8-17.0% vs 5.3-13.3% with placebo 1, 4
- Discontinuation due to hyperkalemia: only 1.2-1.7% of patients 1, 5
- No deaths attributed to hyperkalemia in clinical trials 7
Critical pitfall to avoid: Do not withhold finerenone solely due to fear of hyperkalemia in appropriate candidates. The kidney and cardiovascular benefits substantially outweigh this manageable risk when proper monitoring protocols are followed 9.
The drug can be continued even if eGFR falls below 25 mL/min/1.73 m² during treatment, as long as potassium remains acceptable and the medication is tolerated 12.